Q4 EPS Estimates for Cytosorbents Raised by Zacks Small Cap

Cytosorbents Corporation (NASDAQ:CTSO) – Equities researchers at Zacks Small Cap increased their Q4 2025 earnings estimates for Cytosorbents in a research note issued to investors on Tuesday, January 13th. Zacks Small Cap analyst T. Kerr now expects that the medical research company will earn ($0.04) per share for the quarter, up from their previous estimate of ($0.05). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents’ FY2026 earnings at ($0.08) EPS.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, November 13th. The medical research company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. Cytosorbents had a negative net margin of 27.77% and a negative return on equity of 101.14%. The firm had revenue of $9.49 million for the quarter, compared to analyst estimates of $10.02 million.

CTSO has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Monday. Finally, HC Wainwright dropped their target price on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a report on Friday, November 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.38.

Cytosorbents Trading Down 1.6%

NASDAQ CTSO opened at $0.72 on Thursday. The stock’s 50-day simple moving average is $0.70 and its two-hundred day simple moving average is $0.87. Cytosorbents has a twelve month low of $0.60 and a twelve month high of $1.61. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $45.09 million, a price-to-earnings ratio of -3.99 and a beta of 1.32.

Institutional Investors Weigh In On Cytosorbents

A number of large investors have recently made changes to their positions in CTSO. Avenir Corp increased its position in Cytosorbents by 0.3% during the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares during the period. Citadel Advisors LLC increased its position in shares of Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the period. Goldman Sachs Group Inc. raised its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares in the last quarter. CM Management LLC lifted its holdings in Cytosorbents by 3.1% in the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after buying an additional 38,128 shares during the period. Finally, Vanguard Group Inc. boosted its position in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.